secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001104659-25-054712
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura extends debt maturity and LTX-03 NDA deadline to Dec 31, 2025; warns of cash crunch
--------------------------------------------------------------------------------

- Principal balance on AD Pharma promissory note $7,994,279 plus ~$683,000 accrued interest as of May 29, 2025.
- Maturity of note extended from May 31, 2025 to December 31, 2025.
- FDA NDA acceptance deadline for LTX-03 (hydrocodone/APAP) extended from May 31, 2025 to December 31, 2025 per Amendment #12.
- Warrant to purchase 10M shares at $0.01 also extended to expire Dec 31, 2025.
- Company states without additional financing by mid-June 2025 it will shut down or seek bankruptcy, risking total loss of shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465925054712/0001104659-25-054712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465925054712/tm2516608d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-054712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer